{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T11:28:51Z","timestamp":1758281331187,"version":"3.44.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s43441-025-00830-x","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T13:53:34Z","timestamp":1750514014000},"page":"909-918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analysis of Phase I Clinical Trial Design of Anti-Cancer Agents"],"prefix":"10.1007","volume":"59","author":[{"given":"Juhee","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haesook","family":"Bok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taeyoun","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"830_CR1","unstructured":"Institute IQVIA. Nov 2022."},{"key":"830_CR2","doi-asserted-by":"crossref","unstructured":"Hanahan D. (2022) Hallmarks of Cancer: New Dimensions: Cancer Discovery. 31\u201346.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"830_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","volume":"100","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Weinberg RA. The hallmark of Cancer. Cell. 2000;100:57\u201370.","journal-title":"Cell"},{"key":"830_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"830_CR5","unstructured":"Institute IQVIA. Jan 2023."},{"key":"830_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/nrd.2016.19","volume":"15","author":"M Shea","year":"2016","unstructured":"Shea M, Ostermann L, Hohman R, Roberts S, Kozak M, Dull R, Allen J, Sigal E. Impact of breakthrough therapy designation on cancer drug development. Nat Rev Drug Discovery. 2016;15:152.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"830_CR7","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2000.18.3.684","volume":"8","author":"EA Eisenhauer","year":"2000","unstructured":"Eisenhauer EA, O\u2019Dwyer PJ, Christian M, Humphrey JS. Phase I clinical trial design in cancer drug development. J Clin Oncol. 2000;8(3):684\u201392.","journal-title":"J Clin Oncol"},{"issue":"2","key":"830_CR8","first-page":"106","volume":"13","author":"KM Wong","year":"2016","unstructured":"Wong KM, Capasso A, Eckhardt SG. The changing landscape of phase I trials in oncology. Clin Oncol. 2016;13(2):106\u201317.","journal-title":"Clin Oncol"},{"key":"830_CR9","unstructured":"FDA Guidance Document: Expansion Cohorts: Use in First-in-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics. (2022)."},{"issue":"22","key":"830_CR10","doi-asserted-by":"publisher","first-page":"6719","DOI":"10.1158\/1078-0432.CCR-06-2860","volume":"13","author":"BHL Goulart","year":"2007","unstructured":"Goulart BHL, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007;13(22):6719\u201326.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"830_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/cncr.22878","volume":"110","author":"SA Koyfman","year":"2007","unstructured":"Koyfman SA, Agrawal M, Garrett-Mayer, Krohmal EB, Wolf E, Emanuel EJ, Gross CP. Risks and benefits associated with novel phase 1 oncology trial designs. Cancer. 2007;110(5):1115\u201323.","journal-title":"Cancer"},{"issue":"10","key":"830_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"CL Tourneau","year":"2009","unstructured":"Tourneau CL, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009;101(10):708\u201320.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"830_CR13","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1158\/1078-0432.CCR-09-1961","volume":"16","author":"SP Ivy","year":"2010","unstructured":"Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L. Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: A report from the clinical trial design task force of the National Cancer Institute investigational drug steering committee. Clin Cancer Res. 2010;16(6):1726\u201336.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"830_CR14","first-page":"1","volume":"3","author":"TM Braun","year":"2014","unstructured":"Braun TM. The current design of oncology phase I clinical trials: progressing from algorithms to statistical models. Chin Clin Oncol. 2014;3(1):1\u201311.","journal-title":"Chin Clin Oncol"},{"issue":"16","key":"830_CR15","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1158\/1078-0432.CCR-14-0521","volume":"20","author":"CJ Paller","year":"2014","unstructured":"Paller CJ, Bradbury PA, Ivy SP, Seymour L, LoRusso PM, Baker L, Rubinstein L, Huang E, Collyar D, Groshen S, Reeves, Ellis SLM, Sargent DJ, Rosner GL, LeBlanc ML, Ratain MJ. Design of phase I combination trials: recommendations of the clinical trial design task force of the NCI investigational drug steering committee. Clin Cancer Res. 2014;20(16):4210\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"830_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/annonc\/mdu516","volume":"26","author":"MK Riviere","year":"2015","unstructured":"Riviere MK, Tourneau C, Paoletti X, Dubois F, Zohar S. Designs of drug-combination phase I trials in oncology: a systematic review of the literature. Ann Oncol. 2015;26(4):669\u201374.","journal-title":"Ann Oncol"},{"key":"830_CR17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40290-017-0205-7","volume":"31","author":"C O\u2019Brien","year":"2017","unstructured":"O\u2019Brien C, Carter L, Cook N, Dean E. Novel early phase clinical trial design in oncology. Pharm Med. 2017;31:297\u2013307.","journal-title":"Pharm Med"},{"issue":"81","key":"830_CR18","first-page":"1","volume":"6","author":"NA Wages","year":"2018","unstructured":"Wages NA, Chiuzan C, Panageas KS. Design considerations for early-phase clinical trials of immune-oncology agents. J Immunother Cancer. 2018;6(81):1\u201310.","journal-title":"J Immunother Cancer"},{"key":"830_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1093\/annonc\/mdx795","volume":"29","author":"F Yan","year":"2018","unstructured":"Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I\u2013II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2018;29:694\u20139.","journal-title":"Ann Oncol"},{"key":"830_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ctrv.2019.01.001","volume":"74","author":"J Verweija","year":"2019","unstructured":"Verweija J, Hendrsb HR, Zwierzinac H, on behalf of the Cancer Drug Development Forum, Hanausked V, Wachecke. O, Collignonf. P, Bruzzig. J, Grossh. T, Riehli. F. Innovation in oncology clinical trial design. Cancer Treat Rev. 2019;74:15\u201320. Bretzj., Dollinsh, I. Radtkek).","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"830_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/eahr.500033","volume":"41","author":"BA Sisk","year":"2019","unstructured":"Sisk BA, DuBois J, Hobbs BP, Kodish E. The future of study design in Early-Phase Cancer research. Ethics Hum Res. 2019;41(6):2\u201311.","journal-title":"Ethics Hum Res"},{"key":"830_CR22","first-page":"773","volume":"16","author":"JJ Adashek","year":"2019","unstructured":"Adashek JJ, LoRusso PM, Hong DS, Kurzrock R. Phase I trials as valid therapeutic options for patients with cancer. Clin Oncol. 2019;16:773\u20138.","journal-title":"Clin Oncol"},{"key":"830_CR23","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41416-021-01412-y","volume":"125","author":"A Iasonos","year":"2021","unstructured":"Iasonos A, O\u2019Quigley J. Randomised phase 1 clinical trials in oncology. Br J Cancer. 2021;125:920\u20136.","journal-title":"Br J Cancer"},{"key":"830_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/jmp2030018","volume":"2","author":"A Rossi","year":"2021","unstructured":"Rossi A, Pilotto S, Carbognin L, Ferrara MG, Belluomini L, Daniele G, Bria E. Modern challenges for Early-Phase clinical trial design and biomarker discovery in metastatic Non-Small-Cell lung Cancer. J Mol Pathol. 2021;2:207\u201322.","journal-title":"J Mol Pathol"},{"key":"830_CR25","doi-asserted-by":"crossref","unstructured":"Jaki T, Burdon A, Chen X, Mozgunov P, Zheng H, Baird R. (2023) Early phase clinical trials in oncology: realising the potential of seamless designs. Eur J Cancer. 189.","DOI":"10.1016\/j.ejca.2023.05.005"},{"key":"830_CR26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/pst.2291","volume":"22","author":"A Phillips","year":"2023","unstructured":"Phillips A, Mondal S. Improving early phase oncology clinical trial design:the case for finding the optimal biological dose. Pharm Stat. 2023;22:739\u201347.","journal-title":"Pharm Stat"},{"issue":"4","key":"830_CR27","first-page":"587","volume":"34","author":"SJ Heo","year":"2023","unstructured":"Heo SJ, Lee JW. A comparative study of dose escalation designs in oncology phase 1 clinical trials. J Korean Data Inform Sci Soc. 2023;34(4):587\u2013606.","journal-title":"J Korean Data Inform Sci Soc"},{"key":"830_CR28","unstructured":"Korea. Pharmaceutical Information Center. www.health.kr."},{"issue":"1","key":"830_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4110\/in.2022.22.e4","volume":"22","author":"D Moon","year":"2022","unstructured":"Moon D, Tae N, Park Y, Lee SW, Kim DH. Development of bispecific antibody for Cancer immunotherapy: focus on T cell engaging antibody. Immune Netw. 2022;22(1):1\u201322.","journal-title":"Immune Netw"},{"key":"830_CR30","doi-asserted-by":"crossref","unstructured":"Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. (2019) Seamless designs: current practice and considerations for Early-Phase drug development in oncology. 111(2), 118\u201328.","DOI":"10.1093\/jnci\/djy196"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00830-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:54:21Z","timestamp":1758228861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["830"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00830-x","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"type":"print","value":"2168-4790"},{"type":"electronic","value":"2168-4804"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}